AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Cluster Headache Syndrome (Cluster Headache) Pipeline Review, H1 2019 Report Featuring Clexio Biosciences, Crossject, Eli Lilly and Co, Novartis, Teva Pharmaceutical & TrioxBio - ResearchAndMarkets.com

May 23, 2019

DUBLIN--(BUSINESS WIRE)--May 23, 2019--

The “Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Cluster Headache Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5ajxua

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005447/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Analgesics

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/23/2019 09:40 AM/DISC: 05/23/2019 09:40 AM

http://www.businesswire.com/news/home/20190523005447/en

All contents © copyright 2019 The Associated Press. All rights reserved.